Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 2, 2011, Pages 183-193

  Ohmori, Hitoshi ^a   Luo, Yi ^a   Kuniyasu, Hiroki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

AGE; colorectal cancer; HMGB1; macrophage; metastasis; RAGE

Indexed keywords

4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; DNA; HIGH MOBILITY GROUP B1 PROTEIN; TOLL LIKE RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; COLORECTAL CANCER; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INHIBITION KINETICS; INTRACELLULAR SIGNALING; KUPFFER CELL; MACROPHAGE; MONOCYTE; PROTEIN SECRETION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

COLORECTAL NEOPLASMS; DENDRITIC CELLS; GLYCOSYLATION END PRODUCTS, ADVANCED; HISTONES; HMGB1 PROTEIN; HUMANS; KUPFFER CELLS; MACROPHAGES; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RECEPTORS, IMMUNOLOGIC; TOLL-LIKE RECEPTORS;

EID: 78651350104     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.546785     Document Type: Review

References (100)

1. Lee KL, Pentecost BT, DAnna JA, et al. Characterization of cDNA sequences corresponding to three distinct HMG-1 mRNA species in line CHO chinese hamster cells and cell cycle expression of the HMG-1 gene. Nucleic Acids Res 1987;15:5051-68
2. Rauvala H, Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem 1987;262:16625-35
3. Parkkinen J, Raulo E, Merenmies J, et al. Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 1993;268:685-91
4. Tanji N, Markowitz GS, Fu C, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000;11:1656-66
5. Merenmies J, Pihlaskari R, Laitinen J, et al. 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem 1991;266:16722-9
6. Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta 2010;1799:101-13
7. Chaney SG, Vaisman A. Specificity of platinum-DNA adduct repair. J Inorg Biochem 1999;77:71-81
8. Fages C, Nolo R, Huttunen HJ, et al. Regulation of cell migration by amphoterin. J Cell Sci 2000;113:611-20
9. Volp K, Brezniceanu ML, Bosser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006;55:234-42
10. Tang D, Kang R, Livesey KM, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010;190:881-92
11. Czura CJ, Wang H, Tracey KJ. Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001;7:315-21
12. Degryse B, Bonaldi T, Scaffidi P, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001;152:1197-206
13. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51
14. Tang D, Kang R, Zeh HJ, et al. HMGB1, oxidative stress, and disease. Antioxid Redox Signal 2010: published online 24 october 2010, doi:10.1089/ars.2010.3356
15. Sasahira T, Sasaki T, Kuniyasu H. Interleukin-15 and transforming growth factor alpha are associated with depletion of tumor-associated macrophages in colon cancer. J Exp Clin Cancer Res 2005;24:69-74
16. Kuniyasu H, Chihara Y, Kondo H, et al. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 2003;10:1863-8
17. Ohmori H, Luo Y, Fujii K, et al. Dietary linoleic acid and glucose enhances azoxymethane-induced colon cancer and the metastasis through the expression of high mobility group box 1. Pathobiol 2010;77:210-7
18. Fujii K, Luo Y, Sasahira T, et al. Co-treatment with deoxycholic acid and azoxymethane accelerates the secretion of HMGB1 in IEC6 intestinal epithelial cells. Cell Prolif 2009;42:701-9
19. Tesniere A, Apetoh L, Ghiringhelli F, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008;20:504-11
20. Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelialcell surface. J Biol Chem 1992;267:14987-97
21. Kostova N, Zlateva S, Ugrinova I, et al. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010;337:251-8
22. Sasahira T, Akama Y, Fujii K, et al. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 2005;446:411-5
23. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008;4:285-93
24. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60
25. Yamamoto K, Kitayama W, Denda A, et al. Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac. Pathobiology 2006;73:317-24
26. Kuniyasu H, Oue N, Wakikawa A, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002;196:163-70
27. Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003;10:445-8
28. Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 2003;104:722-7
29. Schraml P, Shipman R, Colombi M, et al. Identification of genes differentially expressed in normal lung and non-small cell lung carcinoma tissue. Cancer Res 1994;54:5236-40
30. Bartling B, Hofmann HS, Weigle B, et al. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 2005;26:293-301
31. Riuzzi F, Sorci G, Donato R. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem 2006;281:8242-53
32. Riuzzi F, Sorci G, Donato R. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol 2007;171:947-61
33. Tateno T, Ueno S, Hiwatashi K, et al. Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2009;16:440-6
34. Sasahira T, Kirita T, Oue N, et al. High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 2008;99:1806-12
35. Gardella S, Andrei C, Ferrera D, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002;3:995-1001
36. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5
37. Huttunen HJ, Kuja-Panula J, Sorci G, et al. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000;275:40096-105
38. Penzo M, Molteni R, Suda T, et al. Inhibitor of NF-kappab kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis. J Immunol 2010;184:4497-509
39. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med 2007;7:711-24
40. Yamagishi S, Yonekura H, Yamamoto Y, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997;272:8723-30
41. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223-34
42. Bucciarelli LG, Ananthakrishnan R, Hwang YC, et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 2008;57:1941-51
43. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-97
44. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 1998;44:1013-23
45. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimers disease. Nature 1996;382:685-91
46. Treins C, Giorgetti-Peraldi S, Murdaca J, et al. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 2001;276:43836-41
47. Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002;16:1928-30
48. Yamamoto Y, Yamagishi S, Yonekura H, et al. Roles of the AGE-RAGE system in vascular injury in diabetes. Ann NY Acad Sci 2000;902:163-70
49. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann NY Acad Sci 2008;1131:225-34
50. Sundar SS, Ganesan TS. Role of lymphangiogenesis in cancer. J Clin Oncol 2007;25:4298-307
51. Bosserhoff AK, Hein R, Bogdahn U, et al. Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 1996;271:490-5
52. Poser I, Golob M, Buettner R, et al. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003;23:2991-8
53. Sasahira T, Kirita T, Kurihara M, et al. MIA-dependent angiogenesis and lymphangiogenesis are closely associated with progression, nodal metastasis and poor prognosis in tongue squamous cell carcinoma. Eur J Cancer 2010;46:2285-94
54. Li Y, Gong W, Zhang L, et al. Expression and purification of the fusion protein HMGB1Abox-TMD1, a novel HMGB1 antagonist. Biochemistry 2010;75:466-71
55. Schierbeck H, Wahamaa H, Andersson U, et al. Immunomodulatory drugs regulate HMGB1 release from activated human monocytes. Mol Med 2010;16:343-51
56. Wang H, Zhu S, Zhou R, et al. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med 2008;10:e32
57. Abdulahad DA, Westra J, Limburg PC, et al. HMGB1 in systemic lupus erythematosus: its role in cutaneous lesions development. Autoimmun Rev 2010;9:661-5
58. Gao Q, Ma LL, Gao X, et al. TLR4 mediates early graft failue after intraportal islet transplantation. Am J Transplant 2010;10:1588-96
59. Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010;107:11942-7
60. Kuniyasu H, Sasaki T, Sasahira T, et al. Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology 2004;71:129-36
61. Kuniyasu H, Yano S, Sasaki T, et al. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 2005;166:751-60
62. Kusume A, Sasahira T, Luo Y, et al. Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 2009;76:155-62
63. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappab require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999;274:19919-24
64. Aznar S, Lacal JC. Rho signals to cell growth and apoptosis. Cancer Lett 2001;165:1-10
65. Esteve P, Embade N, Perona R, et al. Rho-regulated signals induce apoptosis in vitro and in vivo by a p53-independent, but BCL2 dependent pathway. Oncogene 1998;17:1855-69
66. Lakics V, Vogel SN. Lipopolysaccharide and ceramide use divergent signaling pathways to induce cell death in murine macrophages. J Immunol 1998;161:2490-500
67. Embade N, Valeron PF, Aznar S, et al. Apoptosis induced by Rac GTPase correlates with induction of FasL and ceramides production. Mol Biol Cell 2000;11:4347-58
68. Xu W, Liu LZ, Loizidou M, et al. The role of nitric oxide in cancer. Cell Res 2002;12:311-20
69. Xie K, Fidler IJ. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev 1998;17:55-75
70. Feng B, Yao PM, Li Y, et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol 2003;5:781-92
71. Luo Y, Ohmori H, Fujii K, et al. HMGB1 attenuates anti-metastatic defense of the liver in colorectal cancer. Eur J Cancer 2010;46:791-9
72. Moriwaka Y, Luo Y, Ohmori H, et al. HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology 2010;77:17-23
73. Kikkawa H, Imafuku H, Tsukada H, et al. Possible role of immune surveillance at the initial phase of metastasis produced by B16BL6 melanoma cells. FEBS Lett 2000;467:211-6
74. Hermanowicz A, Gibson PR, Jewell DP. Tumour related inhibition of macrophage chemotaxis in patients with colon cancer. Gut 1987;28:416-22
75. Albertoni M, Shaw PH, Nozaki M, et al. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002;21:4212-9
76. Gannon PO, Alam Fahmy M, Begin LR, et al. Presence of prostate cancer metastasis correlates with lower lymph node reactivity. Prostate 2006;66:1710-20
77. Timmers M, Vekemans K, Vermijlen D, et al. Interactions between rat colon carcinoma cells and Kupffer cells during the onset of hepatic metastasis. Int J Cancer 2004;112:793-802
78. Martens JH, Kzhyshkowska J, Falkowski-Hansen M, et al. Differential expression of a gene signature for scavenger/lectin receptors by endothelial cells and macrophages in human lymph node sinuses, the primary sites of regional metastasis. J Pathol 2006;208:574-89
79. Fong Y, Kemeny N, Paty P, et al. Treatment of colorectal cancer: hepatic metastasis. Semin Surg Oncol 1996;12:219-52
80. Leclercq IA, Da Silva Morais A, Schroyen B, et al. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007;47:142-56
81. Cheng BQ, Jia CQ, Liu CT, et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008;40:446-52
82. Wertel I, Barczynski B, Kotarski J. The role of dendritic cells in cytotoxic immune response regulation in ovarian cancer micro-environment. Front Biosci 2008;13:2177-90
83. Schnurr M, Chen Q, Shin A, et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005;105:2465-72
84. Shunyakov L, Ryan CK, Sahasrabudhe DM, et al. The influence of host response on colorectal cancer prognosis. Clin Colorectal Cancer 2004;4:38-45
85. Zeh HJ, Stavely-OCarroll K, Choti MA. Vaccines for colorectal cancer. Trends Mol Med 2001;7:307-13
86. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5:1249-55
87. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487-96
88. Gnanasekar M, Thirugnanam S, Ramaswamy K. Short hairpin rna (shrna) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 2009;34:425-31
89. Coffey JC, Wang JH, Kelly R, et al. Tolerization with BLP down-regulates HMGB1 a critical mediator of sepsis-related lethality. J Leukoc Biol 2007;82:906-14
90. Yang QW, Xiang J, Zhou Y, et al. Targeting HMGB1/TLR4 signaling as a novel approach to treatment of cerebral ischemia. Front Biosci 2010;2:1081-91
91. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010;1799:149-56
92. Schmidt AM, Yan SD, Brett J, et al. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993;91:2155-68
93. Kalea AZ, See F, Harja E, et al. Alternatively spliced RAGEv1 inhibits tumorigenesis via suppression of JNK signaling. Cancer Res 2010;70:5628-38
94. Ulloa L, Ochani M, Yang H, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002;99:12351-6
95. Yamamoto T, Ono T, Ito T, et al. Hemoperfusion with a high-mobility group box 1 adsorption column can prevent the occurrence of hepatic ischemia-reperfusion injury in rats. Crit Care Med 2010;38:879-85
96. Suda K, Takeuchi H, Hagiwara T, et al. Spherical sulfated cellulose adsorbs high-mobility-group box chromosomal protein 1 in vitro and in vivo. ASAIO J 2010;56:210-4
97. Xu J, Futakuchi M, Iigo M, et al. Involvement of macrophage inflammation protein 1alpha (MIP1alpha) in promotion of rat lung and mammary carcinogenic activity of nano-scale titanium dioxide particles administered by intra-pulmonary spraying. Carcinogenesis 2010;31:927-35
98. Wang L, Zhang X, Liu L, et al. Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappab expression. Neurosci Lett 2010;471:152-6
99. Wang L, Zhang X, Liu L, et al. Tanshinone ii a down-regulates HMGB1, RAGE, TLR4, NF-kappab expression, ameliorates BBB permeability and endothelial cell function, and protects rat brains against focal ischemia. Brain Res 2010;1321:143-51
100. Tang Y, Lv B, Wang H, et al. PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia. Int Immunopharmacol 2008;8:1646-51